The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Efficacy of B-Cell Targeted Therapy With Rituximab in Patients With Active Moderate to Severe Graves' Orbitopathy: A Randomized Controlled Study
Open accessAbstract
BACKGROUND: Preliminary studies have shown that rituximab (RTX) is effective in the treatment of active Graves' orbitopathy (GO). METHODS: We conducted a double-blind, randomized trial (European Clinical Trials Database [EudraCT] 2007-003910-33) to compare RTX with iv methylprednisolone (ivMP) in patients with active moderate to severe GO. Thirty-two patients were randomized to receive either ivMP (7.5 g) or RTX (2000 or 500 mg). The primary end point was the decrease of the clinical activity score of 2 points or to less than 3 at week 24. Changes of proptosis, lid fissure, diplopia and eye muscle motility, and quality of life score were secondary end points. The number of therapeutic responses, disease reactivation, and surgical procedures required during follow-up and the patients' quality of life were also assessed. RESULTS: The clinical activity score decreased with both treatments but more after RTX at 16, 20, and 24 weeks (P < .04, P < .02, P < .006, respectively), whether 1000 mg RTX twice or 500 mg RTX once was used (P = NS). At 24 weeks 100% of RTX patients improved compared with 69% after ivMP (P < .001). Disease reactivation was never observed in RTX patients but was observed in five after ivMP. Patients treated with RTX scored better motility at 52 weeks in both the right (P = .014) and the left eye (P = .026). Overall rehabilitative surgical procedures carried out during follow-up (at 76 wk) were 12 in 16 ivMP patients and 5 in 15 RTX patients (P = .049). CONCLUSIONS: The results of this trial confirm preliminary reports on a better therapeutic outcome of RTX in active moderate to severe GO, when compared with ivMP, even after a lower RTX dose. The better eye motility outcome, visual functioning of the quality of life assessment, and the reduced number of surgical procedures in patients after RTX seem to suggest a disease-modifying effect of the drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Bahn, R. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0905750 · Cited by 1,552
Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy
Mourits, M. P., Prummel, M. F., Wiersinga, W. M., & Koornneef, L. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.2331047.x · Cited by 1,001
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO
Bartalena, L., Baldeschi, L., Dickinson, A., Eckstein, A., Kendall-Taylor, P., Marcocci, C., Mourits, M., Perros, P., Boboridis, K., Boschi, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0666 · Cited by 795
Self-citationEckstein, A. K., Plicht, M., Lax, H., Neuhäuser, M., Mann, K., Lederbogen, S., Heckmann, C., Esser, J., & Morgenthaler, N. G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2813 · Cited by 477
Bartalena, L., Baldeschi, L., Dickinson, A. J., Eckstein, A., Kendall-Taylor, P., Marcocci, C., Mourits, M. P., Perros, P., Boboridis, K., Boschi, A., et al. (2008) · Thyroid · doi:10.1089/thy.2007.0315 · Cited by 406
Self-citationvan Vollenhoven, R. F., Emery, P., Bingham, C. O., Keystone, E. C., Fleischmann, R. M., Furst, D. E., Tyson, N., Collinson, N., & Lehane, P. B. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201956 · Cited by 390
Intravenous Glucocorticoids for Graves' Orbitopathy: Efficacy and Morbidity
Zang, S., Ponto, K. A., & Kahaly, G. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1962 · Cited by 379
Bartalena, L., Krassas, G. E., Wiersinga, W., Marcocci, C., Salvi, M., Daumerie, C., Bournaud, C., Stahl, M., Sassi, L., Veronesi, G., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2389 · Cited by 370
Self-citationRandomized Controlled Trial of Rituximab in Patients With Graves' Orbitopathy
Stan, M. N., Garrity, J. A., Carranza Leon, B. G., Prabin, T., Bradley, E. A., & Bahn, R. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2572 · Cited by 369
Evens, A. M., Jovanovic, B. D., Su, Y., Raisch, D. W., Ganger, D. R., Belknap, S. M., Dai, M.-S., Chiu, B.-C. C., Fintel, B., Cheng, Y., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq583 · Cited by 353
Salvi, M., Vannucchi, G., Campi, I., Currò, N., Dazzi, D., Simonetta, S., Bonara, P., Rossi, S., Sina, C., Guastella, C., et al. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02325 · Cited by 264
Self-citationClassification of the Eye Changes of Graves' Disease
WERNER, S. C. (1969) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-29-7-982 · Cited by 223
Dickinson, A. J., & Perros, P. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01349.x · Cited by 210
Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves’ disease
Fassi, D. E., Nielsen, C. H., Kjeldsen, J., Clemmensen, O., & Hegedüs, L. (2008) · Gut · doi:10.1136/gut.2007.138305 · Cited by 170
Quality of life in Graves’ ophthalmopathy
Wiersinga, W. M. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.11.001 · Cited by 148
Salvi, M., Vannucchi, G. M., Campi, I., Rossi, S., Bonara, P., Sbrozzi, F., Guastella, C., Avignone, S., Pirola, G., Ratiglia, R., et al. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02119 · Cited by 145
Self-citationPublic Health Relevance of Graves' Orbitopathy
Ponto, K. A., Merkesdal, S., Hommel, G., Pitz, S., Pfeiffer, N., & Kahaly, G. J. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3119 · Cited by 141
Immunotoxicity of monoclonal antibodies
Descotes, J. (2009) · mAbs · doi:10.4161/mabs.1.2.7909 · Cited by 140
Quality of life in thyroid eye disease: impact of quality of care
Estcourt, S., Quinn, A. G., & Vaidya, B. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0055 · Cited by 124
Pathogenesis of Graves’ orbitopathy: A 2010 update
Smith, T. J. (2010) · Journal of Endocrinological Investigation · doi:10.1007/bf03346614 · Cited by 97
Fassi, D. E., Banga, J. P., Gilbert, J. A., Padoa, C. J., Hegedűs, L. D., & Nielsen, C. H. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.09.007 · Cited by 93
Potential Utility of Rituximab for Graves' Orbitopathy
Salvi, M., Vannucchi, G. M., & Beck‐Peccoz, P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1804 · Cited by 91
Self-citationMeasuring disease activity to predict therapeutic outcome in Graves’ ophthalmopathy
Terwee, C. B., Prummel, M. F., Gerding, M. N., Kahaly, G. J., Dekker, F. W., & Wiersinga, W. M. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02186.x · Cited by 85
Small Dose of Rituximab for Graves Orbitopathy: New Insights Into the Mechanism of Action
Salvi, M. (2012) · Archives of Ophthalmology · doi:10.1001/archopthalmol.2011.1215 · Cited by 81
Self-citationMitchell, A. L., Gan, E. H., Morris, M., Johnson, K., Neoh, C., Dickinson, A. J., Perros, P., & Pearce, S. H. S. (2013) · Clinical Endocrinology · doi:10.1111/cen.12141 · Cited by 79
Vannucchi, G. M., Campi, I., Bonomi, M., Covelli, D., Dazzi, D., Currò, N., Simonetta, S., Bonara, P., Persani, L., Guastella, C., et al. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04191.x · Cited by 66
Self-citationLeo, M., Marcocci, C., Pinchera, A., Nardi, M., Megna, L., Rocchi, R., Latrofa, F., Altea, M. A., Mazzi, B., Sisti, E., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2077 · Cited by 66
Vannucchi, G. M., Covelli, D., Campi, I., Origo, D., Currò, N., Cirello, V., Dazzi, D., Beck‐Peccoz, P., & Salvi, M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0611 · Cited by 63
Self-citationBurch, H. B., & Bahn, R. S. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00081-2 · Cited by 56
Haggerty, H. R., Richardson, S., Mitchell, K. W., & Dickinson, A. J. (2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.3.356 · Cited by 51
Cited by
Smith, T. J., & Hegedüs, L. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510030 · Cited by 1,257
Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0479 · Cited by 1,054
Self-citationBartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G. J., Marcocci, C., Perros, P., Salvi, M., & Wiersinga, W. M. (2016) · European Thyroid Journal · doi:10.1159/000443828 · Cited by 943
Self-citationTeprotumumab for Thyroid-Associated Ophthalmopathy
Smith, T. J., Kahaly, G. J., Ezra, D. G., Fleming, J. C., Dailey, R. A., Tang, R. A., Harris, G. J., Antonelli, A., Salvi, M., Goldberg, R. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614949 · Cited by 756
Self-citationTeprotumumab for the Treatment of Active Thyroid Eye Disease
Douglas, R. S., Kahaly, G. J., Patel, A., Sile, S., Thompson, E. H. Z., Perdok, R., Fleming, J. C., Fowler, B. T., Marcocci, C., Marinò, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910434 · Cited by 752
Self-citation
Metadata
- Authors
- Salvi, M., Vannucchi, G., Currò, N., Campi, I., Covelli, D., Dazzi, D., Simonetta, S., Guastella, C., Pignataro, L., Avignone, S., & Beck-Peccoz, P.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-02
- Volume
- 100
- Issue
- 2
- Pages
- 422-431
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2099402970
- Cited by
- 412
- References
- 31
- FWCI
- 14.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.